Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 19:28:e3304.
doi: 10.1590/1518-8345.3326.3304. eCollection 2020.

Dosage of heparin for patency of the totally implanted central venous catheter in cancer patients

[Article in English, Portuguese, Spanish]
Francisca Jane Gomes de Oliveira  1   2 , Andrea Bezerra Rodrigues  3 , Islane Costa Ramos  4 , Joselany Áfio Caetano  4
Affiliations
Review

Dosage of heparin for patency of the totally implanted central venous catheter in cancer patients

[Article in English, Portuguese, Spanish]
Francisca Jane Gomes de Oliveira et al. Rev Lat Am Enfermagem. .

Abstract
in English, Portuguese, Spanish

Objective: to analyze the evidence available in the literature about the lowest necessary dose of heparin to maintain the patency of the totally implanted central venous catheter in adult cancer patients.

Method: an integrative literature review, carried out in the following databases: Literatura Latino-Americana e do Caribe em Ciências de Saúde, Sciverse Scopus, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, including thirteen studies.

Results: the evidence showed that the dose of heparin (300 IU/ml) is the most used in maintaining the patency of the totally implanted central venous catheter.

Conclusion: according to the selected studies, the lowest dose of heparin found in maintaining the patency of the totally implanted central venous catheter in cancer patients was 10 UN/ml with a volume of 5 ml of the heparin solution.

Objetivo:: analisar as evidências disponíveis na literatura sobre a menor dose necessária de heparina para manter a patência do cateter venoso central totalmente implantado em pacientes oncológicos adultos.

Método:: revisão integrativa da literatura, realizada nas bases de dados: Literatura Latino-Americana e do Caribe em Ciências de Saúde, Sciverse SCOPUS, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, sendo incluídos treze estudos.

Resultados:: as evidências mostraram que a dose de heparina (300 UI/ml), é a mais utilizada na manutenção da patência do cateter venoso central totalmente implantado.

Conclusão:: de acordo com os estudos selecionados a menor dose de heparina encontrada na manutenção da patência do cateter venoso central totalmente implantado em pacientes oncológicos, foi de 10 UN/ml com um volume de 5 ml da solução de heparina.

Objetivo:: analizar la evidencia disponible en la literatura sobre la dosis más baja de heparina necesaria para mantener la permeabilidad del catéter venoso central totalmente implantado en pacientes oncológicos adultos.

Método:: revisión integradora de la literatura realizada en las siguientes bases de datos: Literatura Latinoamericana y del Caribe en Ciencias de la Salud, Sciverse Scopus, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, con la inclusión de trece estudios.

Resultados:: las pruebas demostraron que la dosis de heparina (300 UI/ml) es la más utilizada para mantener la permeabilidad del catéter venoso central totalmente implantado.

Conclusión:: según los estudios seleccionados, la dosis más baja de heparina encontrada en el mantenimiento de la permeabilidad del catéter venoso central totalmente implantado en pacientes oncológicos fue de 10 UN/ml con un volumen de 5 ml de solución de heparina.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flowchart of the selection process for the primary studies. Fortaleza, CE, Brazil, 2018
*LILACS = Literatura Latino-Americana e do Caribe em Ciências de Saúde; †CINAHL = Cumulative Index to Nursing and Allied Health Literature; ‡COCHRANE = Cochrane Central Register of Controlled Trials, §CVC-TI = Totally Implanted Central Venous Catheter
See this image and copyright information in PMC

References

    1. Girda E, Phaeton R, Goldberg GL, Kuo D. Extending the interval for port-a-cath maintenance. Modern Chemother. 2013 Oct;2(2):15–18. doi: 10.4236/mc.2013.22003. - DOI
    1. Honório RPP, Caetano JA, Almeida PC. Validation of standard operating procedures in nursing care of patients with totally implanted catheters. Rev Bras Enferm. 2011 Set-Out;64(5):882–889. doi: 10.1590/S0034-71672011000500013. - DOI - PubMed
    1. Palese A, Baldassar D, Rupil A, Bonanni G, Capellari Maria T, Contessi D, et al. Maintaining patency in totally implantable venous access devices (TIVAD): a time-to-event analysis of different lock irrigation intervals. Eur J Oncol Nurs. 2014 Feb;18(1):66–71. doi: 10.1016/j.ejon.2013.09.002. - DOI - PubMed
    1. Infusion Nurses Society Infusion nursing standards of practice. [Sept 10, 2018];J Infus Nurs. 2016 Jan-Feb;39(1S) [Internet] Available from: http://source.yiboshi.com/20170417/1492425631944540325.pdf.
    1. Hill J, Broadhurst D, Miller K, Cook C, Dumanski J, Friesen N, et al. Occlusion management guideline for central venous access devices (CVADs) [Sept 10, 2018];Vasc Access. 2013 7(Supplement 1) [Internet] Available from: http://www.improvepicc.com/uploads/5/6/5/0/56503399/omg_2013_final_revis....

MeSH terms